KLF4 and pulmonary fibrosis: Collectively, these results demonstrate that KLF4 restoration via administration of APTO-253 has the potential to ameliorate pulmonary fibrosis even in a persistent model with a high degree of relevance to chronic fibrosing conditions such as IPF.